TIME3 was a randomised trial assessing the use of intrapleural fibrinolytic, showing no improvement in breathlessness but improved x-ray appearance and possible mortality benefit. This study provides high quality evidence for the rational use of this medication for patients.
Randomised Controlled Trial of Urokinase versus Placebo for Non-draining Malignant Pleural Effusion
23 February 2018
A recent study published by Prof Najib Rahman, Clinical Director, Oxford Respiratory Trials Unit explains how 15% of people with malignant effusion develop septations (pockets) within the fluid, which are difficult to treat.